Tag: breast cancer liquid biopsy market growth

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theBreast Cancer Liquid Biopsy Market?

The rising incidence of breast cancer is expected to drive the growth of the breast cancer liquid biopsy market in the future. Breast cancer develops in the cells of the breast, typically in the lobules or ducts. The increasing number of breast cancer cases is attributed to factors such as genetic predisposition, hormonal imbalances, aging, lifestyle changes, obesity, alcohol consumption, physical inactivity, radiation exposure, and environmental pollutants. A liquid biopsy is used to detect circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, helping monitor the disease in real-time. It aids in assessing treatment responses, detecting therapy resistance, and identifying genetic mutations for targeted therapies. For instance, in 2025, the American Cancer Society, a US-based nonprofit, expects new breast cancer cases to rise to 319,750, up from 313,510 in 2024. Therefore, the rising number of breast cancer cases is driving the growth of the breast cancer liquid biopsy market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

How Has the Breast Cancer Liquid Biopsy Market Evolved in Recent Years, and What are the Growth Projections for the Forecast Period?

The breast cancer liquid biopsy market has experienced rapid expansion, forecasted to rise from $0.78 billion in 2024 to $0.90 billion in 2025 at a CAGR of 15.0%. Factors driving past growth include advancements in next-generation sequencing (NGS), the rising prevalence of breast cancer, increasing demand for non-invasive diagnostics, adoption of personalized medicine, and greater funding for cancer research.

The breast cancer liquid biopsy market is predicted to expand rapidly, growing to $1.56 billion by 2029 at a CAGR of 14.7%. This growth is driven by technological advancements in liquid biopsy assays, increased adoption of liquid biopsy for early cancer detection, a rising demand for real-time cancer monitoring, expanding applications in precision oncology, and greater investments in liquid biopsy research. Expected trends include AI integration in biopsy analysis, advancements in single-cell sequencing, the development of multi-omics liquid biopsy platforms, improvements in biopsy sensitivity and specificity, and the increased use of digital PCR for precise mutation detection.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

What Are the Latest Innovations Influencing theBreast Cancer Liquid Biopsy Market?

In the breast cancer liquid biopsy market, companies are focusing on developing companion diagnostics to enable personalized treatment. For instance, in January 2023, Guardant Health Inc., a U.S.-based biotechnology company, received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for ORSERDU (elacestrant), a treatment for advanced or metastatic breast cancer patients with ESR1 mutations. This approval allows oncologists to use the test for genomic profiling to identify patients who may benefit from the targeted therapy.

Who Are the Major Industry Players Accelerating Growth in theBreast Cancer Liquid Biopsy Market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Primary Segments of the Breast Cancer Liquid Biopsy Market Are Driving Growth and Industry Transformations?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theBreast Cancer Liquid Biopsy Market?# Market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Breast Cancer Liquid Biopsy Market 2025, By The Business Research Company:

Nanomedicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Sports Medicine Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sports-medicine-global-market-report

Natural Skin Care Products Global Market Report 2025

https://thebusinessresearchcompany.com/report/natural-skin-care-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the breast cancer liquid biopsy market?

In the past few years, the market size for breast cancer liquid biopsy has experienced significant growth. Projections show a surge from $0.78 billion in 2024 to $0.90 billion in 2025, indicating a compound annual growth rate (CAGR) of 15.0%. This notable growth during the historic period can be traced back to developments in next-generation sequencing (ngs), escalating cases of breast cancer, the expanding need for non-invasive diagnostics, the swelling acceptance of personalized medicine, and enhanced funding towards cancer research.

What will be the breast cancer liquid biopsy market size in the future?

In the next few years, the market size of the breast cancer liquid biopsy is predicted to rapidly expand. It is projected to reach $1.56 billion by 2029, with a compound annual growth rate (CAGR) of 14.7%. The causes behind this predicted growth during the forecast period include advancements in liquid biopsy assay technology, an increase in the use of liquid biopsy for initial cancer screening, an escalating demand for real-time cancer monitoring, the expansion of applications in precision oncology, and an increase in investment in liquid biopsy research and development. Significant trends for the forecast period include the use of artificial intelligence in liquid biopsy analysis, breakthroughs in single-cell sequencing, the creation of multi-omics liquid biopsy platforms, enhancements in the sensitivity and specificity of liquid biopsy, and the use of digital pcr for highly accurate mutation detection.

Get your breast cancer liquid biopsy market report here!

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

What main drivers are fueling expansion in the breast cancer liquid biopsy market?

The expectant surge in breast cancer incidences is predicted to boost the expansion of the breast cancer liquid biopsy market. Breast cancer arises in the cells of the breast, commonly in the lobules (milk-producing glands) or ducts (pathways that transport milk to the nipple). The escalating number of breast cancer cases can be attributed to factors such as genetic vulnerability, hormonal disruptions, an aging population, lifestyle alterations, obesity, alcohol intake, lack of physical exercise, radiation exposure, and environmental contaminants. The utilization of a breast cancer liquid biopsy in treatment facilitates the detection of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, thereby monitoring the disease’s progression in real-time. It assists in evaluating treatment response, uncovering resistance to therapy, and pinpointing genetic alterations for targeted treatments. As an illustration, the American Cancer Society, a US-based nonprofit organization committed to cancer research, education, advocacy, and patient aid, predicts that the quantity of new breast cancer cases will escalate to 319,750 in 2025, a surge from 313,510 cases in 2024. As a result, the rising incidences of breast cancer are fueling the expansion of the breast cancer liquid biopsy market.

What key areas define the segmentation of the global breast cancer liquid biopsy market?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

Who are the dominant players expanding their reach in the breast cancer liquid biopsy market?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

What emerging trends are influencing the growth of the breast cancer liquid biopsy market?

Key players in the breast cancer liquid biopsy market, such as Guardant Health Inc., are making strides in the development of novel products like companion diagnostics. These innovative tools are used for personalizing treatment plans by pinpointing patients that might gain from specific treatment methods. They make use of liquid biopsy tools for the detection of biomarkers including, genetic defects, circulating tumor DNA (ctDNA), or protein markers that suggest a positive response to treatment. For instance, in January 2023, Guardant Health Inc., a leading US-based biotech firm, received the FDA’s approval for its Guardant360 CDx liquid biopsy test. It is a companion diagnostic for ORSERDU (elacestrant), a drug developed by Menarini Group for advanced or metastatic breast cancer patients who have ESR1 mutations. The go-ahead from the FDA allows oncologists to utilize the test for a thorough genomic profiling to identify patients who may get further benefits from receiving the targeted therapy. This is a landmark step for Guardant Health since it’s their first FDA approval for breast cancer, which also reinforces its position in precision oncology.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

Which regions are emerging as leaders in the breast cancer liquid biopsy market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Nanomedicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Sports Medicine Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sports-medicine-global-market-report

Natural Skin Care Products Global Market Report 2025

https://thebusinessresearchcompany.com/report/natural-skin-care-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What are the Key Projections for the CAGR of the Breast Cancer Liquid Biopsy Market From 2025 to 2034?

There has been a swift expansion in the size of the breast cancer liquid biopsy market in recent years. The forecasted growth is from $0.78 billion in 2024 up to $0.90 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 15.0%. The said growth during the historic period can be attributed to advancements in next-generation sequencing (ngs), the increasing occurrence of breast cancer, mounting demand for non-invasive diagnostic methods, an upsurge in the acceptance of personalized medicine, and augmented funding directed towards cancer research.

The market size for breast cancer liquid biopsy is predicted to experience substantial expansion in the coming years, eventually reaching a value of $1.56 billion by 2029 with a compound annual growth rate (CAGR) of 14.7%. The escalation in the projection period is due to advancements in liquid biopsy assays technology, the growing use of liquid biopsy for early cancer detection, rising need for real-time cancer monitoring, widespread applications in precision oncology, and increased funding in liquid biopsy research and development. The prediction period will see key trends including the incorporation of artificial intelligence into liquid biopsy analysis, progress in single-cell sequencing, the creation of multi-omics liquid biopsy platforms, enhancement in liquid biopsy sensitivity and specificity, and the use of digital pcr for highly accurate mutation identification.

What Major Innovations Are Driving the Accelerated Growth of the Breast Cancer Liquid Biopsy Market?

The rise in breast cancer incidences is likely to fuel the expansion of the breast cancer liquid biopsy market. Breast cancer, a cancer that originates in the breast cells, commonly in the lobules (milk-producing glands) or ducts (channels that transport milk to the nipple), is witnessing an upsurge due to various factors such as genetic predisposition, hormonal irregularities, aging population, changes in lifestyle, obesity, alcohol intake, physical inactivity, exposure to radiation, and environmental pollutants. A breast cancer liquid biopsy aids in the detection of circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood, thereby facilitating real-time disease monitoring. It assists in evaluating treatment response, spotting therapy resistance, and detecting genetic mutations for targeted therapies. For example, the American Cancer Society, a US-based charitable organization committed to cancer research, education, advocacy, and patient support, forecasts that the number of new breast cancer cases could escalate to 319,750 in 2025, an increase from 313,510 cases in 2024. Hence, the rising incidences of breast cancer are contributing to the growth of the breast cancer liquid biopsy market.

Explore Comprehensive Insights Into The Global Breast Cancer Liquid Biopsy Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Are the Key Industry Players Leading the Charge in the Breast Cancer Liquid Biopsy Market’s Growth?

Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

How Are Market Trends and Shifts Impacting the Growth Trajectory of the Breast Cancer Liquid Biopsy Market?

Leading firms in the breast cancer liquid biopsy market are prioritizing the development of novel products like companion diagnostics. This facilitates personalized treatment procedures by spotting the patients apt for certain treatments. These diagnostics apply liquid biopsy techniques to identify biomarkers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that show a response to treatment. As an example, in January 2023, Guardant Health Inc., a US-derived biotechnology firm, was granted clearance by the Food and Drug Administration (FDA) for its Guardant360 CDx liquid biopsy examination as a companion diagnostic for ORSERDU (elacestrant), a Menarini Group’s treatment for advanced or metastatic breast cancer patients carrying ESR1 mutations. This approval sanctions oncologists to utilize the test for thorough genomic profiling, pinpointing patients who might profit from this specific therapy. It signifies the maiden U.S. Food and Drug Administration (FDA) approval of Guardant Health in breast cancer and amplifies its contribution in precision oncology.

Secure Your Global Breast Cancer Liquid Biopsy Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Which Growth-Oriented Segments of the Breast Cancer Liquid Biopsy Market Are Leading the Industry’s Development?

The breast cancer liquid biopsy market covered in this report is segmented –

1) By Product: Consumables, Kits

2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers

3) By Application: Early Detection Or Screening, Diagnosis, Other Applications

4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:

1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes

2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

What Regions Are Influencing the Dynamics of the Breast Cancer Liquid Biopsy Market?

North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Elements Shape the Definition of the Breast Cancer Liquid Biopsy Market?

A breast cancer liquid biopsy is a minimally invasive test that detects and analyzes tumor-derived materials in a patient’s blood or other bodily fluids. It provides valuable insights into the presence, progression, and genetic profile of breast cancer without requiring a traditional tissue biopsy.

Browse Through More Similar Reports By The Business Research Company:

Nanomedicine Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nanomedicine-global-market-report

Sports Medicine Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/sports-medicine-global-market-report

Natural Skin Care Products Global Market Report 2025

https://thebusinessresearchcompany.com/report/natural-skin-care-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: